Ijeoma Uchegbu, Nanomerics' CSO and Professor of Pharmaceutical Nanoscience, at the University College London School of Pharmacy, has won the Pharmaceutical Scientist of the Year Award from the Royal Pharmaceutical Society. The award was given for her work on developing technologies, specifically, the use of Nanomerics' MET systems, for the treatment of brain diseases.
Nanomerics' CSO Ijeoma Uchegbu today addresses the GPEN (Globalization of Pharmaceutics Education Network) meeting 2012 in Melbourne and talk about "Delivering challenging molecules across biological barriers'.
Nanomerics CSO Prof IF Uchegbu reviews the state of play in the nanomedicines area.
Professor Ijeoma Uchegbu will be presenting within the Next Generation session at Biopharm America 2012. Biopharm America's Next Generation session is reserved for exciting new technology companies. Within this presentation Professor Uchegbu will highlight the benefits of Nanomerics' Molecular Envelope Technology (MET) and present a number of case studies.
Nanomerics is pleased to announce signing of a collaboration agreement with UCL School of Pharmacy, the University of Exeter Physics Department and AMTechnoloy. The £1.2M research contract will fund pharmacological and drug development research on Nanomerics pain therapeutic - METDoloron. METDoloron is an oral peptide pain therapeutic enabled by
Nanomerics and UCL School of Pharmacy scientists announce delivery of a hydrophylic peptide across the blood-brain-barrier (BBB). The BBB prevents transport of most drugs from the blood into the brain. By using a pro-drug approach combined with Nanomerics' MET system the group were able to show that the endogenous anti-pain peptide can be carried across this barrier to provide analgesic activity.